- Obama takes aim at ‘corporate deserters’
- Dick’s Sporting Goods lays off 478 PGA golf pros
- Senators: Cease-fire must allow Israel to defend against rockets, tunnels
- Sierra Leone doctor fighting Ebola catches disease
- Iraq welcomes Russian fighter jets, helicopter gunships into ISIL fight
- John McCain laments: Obama’s ‘self-pity … is really kind of sad’
- GOP offer to fix VA gives $10 billion in emergency funds
- Paul Ryan offers to repair U.S. economic safety net with a single grant stream
- Kim Jong-un builds bond with Putin: $250M Russia-backed addition to key port opens
- Pope Francis meets Meriam Ibrahim, a Sudanese woman sentenced to death
Pfizer 1Q profit drops 15 pct due to lower sales
Question of the Day
Despite sharply lower expenses and taxes, Pfizer Inc.’s first-quarter profit dropped 15 percent, due to cheaper generic competition for multiple medicines and some promotion partnerships with other drugmakers ending.
The world’s second-biggest drugmaker missed Wall Street’s revenue expectations by $730 million, but narrowly beat profit expectations. Its shares fell almost 3 percent in afternoon trading.
The New York-based company has seen its revenue shrink since 2011 as inexpensive copycat pills hurt sales of about 20 off-patent drugs that once brought in billions annually, particularly cholesterol fighter Lipitor, the top-selling drug of all time with peak revenue of nearly $13 billion.
According to Pfizer, “the vast majority” of generic competition will be over by the end of 2015.
Meanwhile, Pfizer said it’s reviewing its options after British rival AstraZeneca PLC on Friday rejected Pfizer’s third acquisition proposal, this time for about $106 billion. Pfizer has been trying since January to get AstraZeneca to discuss a deal that would include Pfizer moving its official domicile -but not its corporate offices - to London, a move that would reduce Pfizer’s income tax rate.
The maker of Viagra said net income was $2.33 billion, or 36 cents per share, for January through March, down from $2.75 billion, or 38 cents per share, a year earlier.
Excluding one-time charges, income was 57 cents per share, two cents less than analysts expected.
Revenue totaled $11.35 billion, down 9 percent. Analysts expected $12.08 billion.
Among Pfizer’s top sellers, sales rose 8 percent to $1.15 billion for pain and fibromyalgia treatment Lyrica and 4 percent to $914 million for immune disorder drug Enbrel. Sales of pneumonia vaccine Prevnar were flat at $927 million, while key newer medicines - rheumatoid arthritis pill Xeljanz and cancer drugs Xalkori and Inlyta - remain disappointing at less than $100 million in the quarter.
“Our new products are just beginning to rev up,” Chief Financial Officer Frank D’Amelio said in an interview with The Associated Press. “The business will pick up.”
Research head Mikael Dolsten said that over the next nine months, Pfizer could win U.S. regulatory approval for two new drugs - an abuse-resistant opioid painkiller and a vaccine against meningitis B - and could get approvals for new uses for two other drugs. In addition, the Food and Drug Administration should decide by end of June whether Pfizer can apply for approval of its breakthrough drug for advanced breast cancer, palbociclib, based on mid-stage patient testing results. Otherwise, Pfizer will have to do a third, larger round of tests, delaying potential approval for well over a year.
Pfizer confirmed its 2014 adjusted profit forecast for earnings per share of $2.20 to $2.30 and revenue of $49.2 billion to $52.3 billion. Analysts expect earnings of $2.24 per share on revenue of $49.77 billion.
For the first time, Pfizer reported separate operating results for its three business segments, to give investors more insight into performance as the company considers eventually breaking off some of its business.
All three segments reported sales at least slightly below 2013’s first quarter. Only the segment that includes vaccines, cancer drugs and consumer health products posted higher income, up 6 percent to $1.06 billion. Pfizer reported income of $1.77 billion for its newer medicines business and $4.05 billion for its older “established” prescription drugs.
Its shares fell 82 cents, or 2.7 percent, to $29.93 in afternoon trading. Its shares have been about so far this year.
TWT Video Picks
Second- and third-stringers eye 2016 if front-runner stumbles
- 'We're coming for you, Barack Obama': Top U.S. official discloses threat from ISIL terrorists
- Obama orders Pentagon advisers to Ukraine
- NAPOLITANO: What if our democracy is a fraud?
- Hamas rejects Kerry's call for cease-fire; Fears grow others could join fight against Israel
- State Department indicates Nouri al-Maliki's days numbered as Iraq prime minister
- Inside China: Massive flight woes and a missile test
- Algerian plane diverted due to storms, second aircraft: 116 missing
- Evidence shows Russia firing artillery into Ukraine: Pentagon
- Obama family set to buy $4.25M desert home in California: report
- Norway expects imminent 'concrete threat' from ISIL terrorists 'within days'
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq